Tweet
DAWN.com
<img alt="" height="1" width="1" />
Pfizer to help patients pay for pricey new cancer med
FiercePharma
Pfizer's Lipitor gap is beginning to fill in. The company won FDA approval for its targeted lung cancer drug Xalkori, which some analysts expect to add a very healthy $2.5 billion in peak sales to the top line. That's partly because the drug carries a ...
FDA approves crizotinib for advanced ALK-positive NSCLCHemOncToday
Pfizer Wins US Approval for Lung Cancer Drug Seen as Filling Lipitor GapBloomberg
Ahead of the Bell: Analyst sees Pfizer drug growthForbes
MarketWatch (press release) -Business Insider -USA Market News
all 32 news articles »
More...